The American Society of Clinical Oncology / American
Urological Association 2008 Clinical
Practice Guideline states: «Men who are taking 5 - ARIs for benign conditions such as lower urinary tract symptoms (LUTS) may benefit from... understanding that the improvement of LUTS relief should be weighed with the potential risks of high - grade prostate cancer from 5 - ARIs.»